NovoCure News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

19.04.17	Novocure™ Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurology Annual Meeting in Boston (Businesswire)
17.04.17	CNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line Chemotherapies after Glioblastoma Recurrence (Businesswire)
04.04.17	Clinical Trial Advancements With Positive Data for Phase 1 and 2 Results Fueling Steady Growth in Biomedical Industry (PR Newswire)
04.04.17	Clinical Trial Advancements With Positive Data for Phase 1 and 2 Results Fueling Steady Growth in Biomedical Industry (PR Newswire)
04.04.17	Gainers & Losers Of The Day: CYCC, NVCR, STDY, ACOR, OREX... (RTTNews)
02.04.17	Optune™ bietet in Kombination mit der Standard-Chemotherapie mit Temozolomid entscheidende Fünf-Jahres-Überlebensrate bei neu diagnostizierten Glioblastom-Patienten (Businesswire)
31.03.17	Combination of Tumor Treating Fields with Standard of Care Therapies, Nab-Paclitaxel and Gemcitabine, Suggests Improved Survival of Patients with Advanced Pancreatic Cancer (Businesswire)
23.02.17	Research Reports Initiation on Medical Equipment Stocks -- Lantheus, Cynosure, Natus Medical, and NovoCure (PR Newswire)
15.02.17	First Patient Enrolled in Novocure’s Phase 3 Pivotal LUNAR Trial Testing Tumor Treating Fields for the Treatment of Advanced Non-Small Cell Lung Cancer After Failing Platinum-Based Therapy (Businesswire)
21.01.17	Johnson & Weaver, LLP Initiates Investigations of Rent-A-Center, Inc., KalVista Pharmaceuticals, Inc., NovoCure Limited and Inotek Pharmaceuticals Corp. (PR Newswire)
12.01.17	Gainers & Losers Of The Day: ACST, APRI, SBBP, NVDQ, NVCR (RTTNews)
10.01.17	Novocure to Report Fourth Quarter and Full Year 2016 Financial Results (Businesswire)
21.12.16	SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of NovoCure Limited (NVCR) (PR Newswire)
08.12.16	Novocure Announces Agenda for Research and Development Day on Dec. 12, 2016 (Businesswire)
17.11.16	Novocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields Plus Chemotherapy may Extend Survival of Patients with Mesothelioma (Businesswire)
14.11.16	Novocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology (Businesswire)
03.11.16	United Healthcare Issues Positive Coverage Decision for Optune (Businesswire)
01.11.16	Novocure Recognizes National Family Caregivers Month by Supporting GBM Heroes Event (Businesswire)
19.09.16	CNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in Glioblastoma (Businesswire)
15.09.16	Novocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academy of Sciences’ Symposium on Bioelectronic Medicine (Businesswire)
14.09.16	Two Institutions Publish Independent Data on Novocure’s Tumor Treating Fields (Businesswire)
01.09.16	International Journal of Cancer Publishes Data Showing Tumor Treating Fields in Combination with Paclitaxel is Therapeutically Effective against Ovarian Cancer Cells in Vitro and in Vivo (Businesswire)
16.08.16	Novocure Converts More Than 500 U.S. Patients to Second Generation Optune within Four Weeks of FDA Approval on July 13 (Businesswire)
08.08.16	Novocure to Present at Upcoming Investor Conferences (Businesswire)
28.07.16	Novocure Reports Second Quarter 2016 Financial Results and Provides Company Update (Businesswire)
28.07.16	Novocure to Host Research and Development Day on Dec. 12, 2016 (Businesswire)
26.07.16	NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma (Businesswire)
14.07.16	NVCR Up On FDA Nod, PeriCoach Now Available OTC, FDA Panel Backs GP2015 (RTTNews)
13.07.16	Novocure Receives FDA Approval for Second Generation Optune System (Businesswire)
30.06.16	Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors (Businesswire)
30.06.16	Novocure to Report Second Quarter 2016 Financial Results (Businesswire)
08.06.16	Novocure to Present at JMP Securities 2016 Life Sciences Conference (Businesswire)
31.05.16	Novocure Receives IDE Approval to Initiate METIS Trial (Businesswire)
24.05.16	EXEL Rises On Trial Data, XNPT Agrees To Be Acquired, NVO Faces FDA Panel Today (RTTNews)
23.05.16	Novocure Enrolls Last Patient in PANOVA Trial of Tumor Treating Fields Plus Chemotherapy in Advanced Pancreatic Cancer (Businesswire)
19.05.16	Novocure Enrolls Last Patient in INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel in Recurrent Ovarian Cancer (Businesswire)
18.05.16	Novocure Announces Presentation of Subgroup Analysis of PANOVA Data Showing Overall Survival Benefit of Tumor Treating Fields Plus Gemcitabine in Advanced Pancreatic Cancer Patients (Businesswire)
13.05.16	Novocure to Present New Preclinical Data Showing Additive Efficacy of Tumor Treating Fields and PD-1 Inhibitors at the American Association of Immunologists’ Annual Meeting 2016 (Businesswire)
11.05.16	Novocure Enters into Employment Agreement with William Doyle (Businesswire)
09.05.16	Novocure Reports First Quarter 2016 Financial Results and Provides Company Update (Businesswire)
06.05.16	Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Support and Inspire Those Affected by Glioblastoma (Businesswire)
05.05.16	Novocure Delivers New Informational Resource for Glioblastoma Brain Cancer (Businesswire)
04.05.16	Blue Cross Blue Shield of Michigan Issues Positive Coverage Decision for Optune (Businesswire)
26.04.16	Novocure’s Optune Now Available at More Than 360 Cancer Treatment Centers in the U.S. (Businesswire)
25.04.16	FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma (Businesswire)
07.04.16	Novocure to Present New Preclinical Data on Tumor Treating Fields at American Association for Cancer Research Annual Meeting 2016 (Businesswire)
05.04.16	Novocure to Report First Quarter 2016 Financial Results (Businesswire)
04.04.16	Novocure und führendes Krebs-Zentrum leiten präklinische Forschungskooperation zur Untersuchung von TTFields ein (Businesswire)
09.03.16	Red Journal Publishes Data Supporting Personalized Treatment Planning to Increase TTFields Efficacy for Patients with Glioblastoma (Businesswire)
03.03.16	Humana Issues Positive Coverage Decision For Optune (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	74.04	2.41 %	K V
ABB	52.12	1.68 %	K V
Geberit	552.80	1.32 %	K V
Alcon	78.04	1.19 %	K V
CieFinRichemont	129.05	1.10 %	K V
Swiss Life Hldg	686.00	-0.64 %	K V
Zurich Insur Gr	555.20	-1.00 %	K V
Holcim	90.66	-1.31 %	K V
Kuehne+Nagel Int	210.60	-1.31 %	K V
Novartis	90.10	-3.14 %	K V

Nachrichten zu NovoCure Limited

Aktien Top/Flop

Meistgelesene Nachrichten